Cargando…
Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa
Artemisinin resistance has emerged and spread in the Greater Mekong Sub-region (GMS), followed by artemisinin-based combination therapy failure, due to both artemisinin and partner drug resistance. More worrying, artemisinin resistance has been recently reported and confirmed in Rwanda. Therefore, t...
Autor principal: | Nsanzabana, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513315/ https://www.ncbi.nlm.nih.gov/pubmed/34645475 http://dx.doi.org/10.1186/s12936-021-03942-5 |
Ejemplares similares
-
Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges
por: Ishengoma, Deus S., et al.
Publicado: (2019) -
Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape
por: Nsanzabana, Christian, et al.
Publicado: (2018) -
Prevalence of Pneumocystosis in Sub-Saharan Africa and Helminth Immune Modulation
por: Fonte, Luis, et al.
Publicado: (2021) -
Challenges in disclosure of adverse events and errors in surgery; perspectives from sub-Saharan Africa
por: Ibrahim, Abdulrasheed, et al.
Publicado: (2012) -
CPP-ZFN: A potential DNA-targeting anti-malarial drug
por: Nain, Vikrant, et al.
Publicado: (2010)